Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

The latest analyst coverage could presage a bad day for Calliditas Therapeutics AB (publ) (STO:CALTX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

Following the downgrade, the latest consensus from Calliditas Therapeutics' six analysts is for revenues of kr483m in 2022, which would reflect a huge 41% improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing kr599m of revenue in 2022. The consensus view seems to have become more pessimistic on Calliditas Therapeutics, noting the measurable cut to revenue estimates in this update.

View our latest analysis for Calliditas Therapeutics

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Calliditas Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 98% annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 32% p.a. over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 28% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Calliditas Therapeutics to grow faster than the wider industry.

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for Calliditas Therapeutics this year. They're also forecasting more rapid revenue growth than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Calliditas Therapeutics going forwards.

Of course, there's always more to the story. We have estimates for Calliditas Therapeutics from its six analysts out until 2024, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.